UBS Lux Equity Fund Biotech USD vs Spiltan Aktiefond Investmentbolag

UBS Lux Equity Fund Biotech USD vs Spiltan Aktiefond Investmentbolag

1. UBS Lux Equity Fund Biotech USD

  • Security

    UBS Lux Equity Fund Biotech USD P-acc

  • Fee

    2.25%

  • ISIN

    LU0069152568

  • Holdings

    5

2. Spiltan Aktiefond Investmentbolag

  • Security

    Spiltan Aktiefond Investmentbolag

  • Fee

    0.24%

  • ISIN

    SE0004297927

  • Holdings

    26

Fund Holdings

We have information about 7 holdings in UBS Lux Equity Fund Biotech USD, where the largest holding is Regeneron Pharmaceuticals (10.04), followed by Moderna (9.21) and Gilead Sciences (4.66). In comparison with Spiltan Aktiefond Investmentbolag, we have 31 holdings where Investor is the largest holding (26.87), followed by Industrivärden (16.57) and Lundbergföretagen (7.74).

All Holdings

Here we compare the holdings in UBS Lux Equity Fund Biotech USD and Spiltan Aktiefond Investmentbolag.

UBS Lux Equity Fund Biotech USD Spiltan Aktiefond Investmentbolag
1. Regeneron Pharmaceuticals Inc
10.04 %
1. Investor B
Sweden
26.87 %
2. Moderna Inc
9.21 %
2. Industrivärden C
Sweden
16.57 %
3. Gilead Sciences Inc
USA
4.66 %
3. Lundbergföretagen B
Sweden
7.74 %
4. BioNTech SE
4.13 %
4. Hexagon B
Sweden
6.08 %
5. Karuna Therapeutics Inc
3.75 %
5. AstraZeneca
Sweden UK
4.43 %
- 6. Indutrade AB
Sweden
4.08 %
- 7. Lifco B
Sweden
4.08 %
- 8. Kinnevik B
Sweden
3.34 %
- 9. Assa Abloy B
Sweden
3.07 %
- 10. Xact OMXS30 ESG ETF
Sweden
3 %
- 11. EQT AB
Sweden
2.4 %
- 12. Atlas Copco B
Sweden
2.37 %
- 13. SCA B
Sweden
1.9 %
- 14. Addtech B
Sweden
1.9 %
- 15. Essity B
Sweden
1.8 %
- 16. Latour B
Sweden
1.77 %
- 17. Investor A
Sweden
1.04 %
- 18. Volvo B
Sweden
0.96 %
- 19. Sandvik
Sweden
0.95 %
- 20. Epiroc B
Sweden
0.91 %
- 21. Ratos B
Sweden
0.77 %
- 22. Atlas Copco A
Sweden
0.62 %
- 23. Industrivärden A
Sweden
0.58 %
- 24. Creades A
Sweden
0.53 %
- 25. SEB A
Sweden
0.48 %
- 26. Bure Equity AB
Sweden
0.3 %

The list of fund holdings was last updated on September 10, 2025.